Chemoinformaics analysis of (E)-oct-3-ene-2,7-dione
| Molecular Weight | 140.182 | nRot | 4 |
| Heavy Atom Molecular Weight | 128.086 | nRig | 3 |
| Exact Molecular Weight | 140.084 | nRing | 0 |
| Solubility: LogS | 0.248 | nHRing | 0 |
| Solubility: LogP | 0.042 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 22 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 8 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 22.9655 |
| nHD | 0 | BPOL | 13.7745 |
| QED | 0.554 |
| Synth | 2.548 |
| Natural Product Likeliness | 1.924 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.006 |
| Pgp-sub | 0.005 |
| HIA | 0.012 |
| CACO-2 | -4.427 |
| MDCK | 0.0000292 |
| BBB | 0.997 |
| PPB | 0.65426 |
| VDSS | 0.57 |
| FU | 0.47578 |
| CYP1A2-inh | 0.058 |
| CYP1A2-sub | 0.515 |
| CYP2c19-inh | 0.044 |
| CYP2c19-sub | 0.707 |
| CYP2c9-inh | 0.014 |
| CYP2c9-sub | 0.696 |
| CYP2d6-inh | 0.006 |
| CYP2d6-sub | 0.646 |
| CYP3a4-inh | 0.007 |
| CYP3a4-sub | 0.268 |
| CL | 5.488 |
| T12 | 0.866 |
| hERG | 0.016 |
| Ames | 0.276 |
| ROA | 0.231 |
| SkinSen | 0.95 |
| Carcinogencity | 0.902 |
| EI | 0.985 |
| Respiratory | 0.805 |
| NR-Aromatase | 0.009 |
| Antiviral | No |
| Prediction | 0.950486 |